OverviewSuggest Edit

Heat Biologics is a clinical-stage company focused on developing its proprietary "ImPACT" (Immune Pan-Antigen Cytotoxic Therapy), a fully allogeneic (“off-the-shelf”) cell-based immunotherapy for use in the treatment of a wide range of cancers.
The Company's ImPACT therapy is a first-in-class, fully human immunotherapy that functions as both an immune stimulator and an antigen-delivery system. ImPACT effectively transforms living allogeneic cells into "osmotic pumps" that continuously secrete cancerous antigens to robustly stimulate the immune system against the targeted cancer. This therapy is applicable to a wide range of cancers.
Heat is currently conducting multiple clinical trials in two indications with its ImPACT therapy based products, HS-410 to treat Non-Muscle Invasive Bladder Cancer (NMIBC) and HS-110 to treat Non-Small Cell Lung Cancer (NSCLC).

TypePublic
Founded2008
HQDurham, US
Websiteheatbio.com

Latest Updates

Employees (est.) (Dec 2018)30(+58%)
Revenue (FY, 2016)$341.6 K
Share Price (Oct 2019)$0.4 (+5%)

Key People/Management at Heat Biologics

Jeffrey Wolf

Jeffrey Wolf

Founder and CEO
Jeff Hutchins

Jeff Hutchins

Chief Scientific and Operating Officer
George Peoples

George Peoples

Chief Medical Advisor
Ann A. Rosar

Ann A. Rosar

Vice President of Finance, Corporate Secretary
Janice Marie McCourt

Janice Marie McCourt

Vice President, Business Development
Lori McDermott

Lori McDermott

Vice President, Clinical Development
Show more

Heat Biologics Office Locations

Heat Biologics has an office in Durham
Durham, US (HQ)
801 Capitola Dr #12
Show all (1)

Heat Biologics Financials and Metrics

Heat Biologics Revenue

Heat Biologics's revenue was reported to be $341.64 k in FY, 2016
USD

Net income (Q2, 2019)

(4.9m)

EBIT (Q2, 2019)

(5.1m)

Market capitalization (11-Oct-2019)

14.3m

Closing stock price (11-Oct-2019)

0.4

Cash (30-Jun-2019)

13.8m
Heat Biologics's current market capitalization is $14.3 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

341.6k

General and administrative expense

2.4m4.0m4.4m4.1m6.4m7.0m

R&D expense

2.7m2.9m2.6m9.3m8.3m16.2m

Operating expense total

6.6m6.8m21.0m13.5m14.9m23.8m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Revenue

220.2k24.2k

General and administrative expense

1.0m1.0m832.1k1.3m893.2k947.4k1.0m1.1m820.6k1.5m1.6m1.2m1.8m1.4m1.6m3.3m1.9m

R&D expense

992.4k533.6k849.4k1.0m503.6k587.2k677.2k500.2k454.9k559.2k1.8m2.2m1.8m2.9m3.5m4.4m3.2m3.4m

Operating expense total

2.0m2.4m1.9m3.1m1.8m4.9m5.3m4.7m2.9m2.5m3.3m3.7m3.0m4.7m5.4m6.1m6.6m5.4m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

4.6m3.7m4.9m7.8m9.8m22.2m

Accounts Receivable

1.8m82.3k14.8k28.5k

Inventories

1.7m

Current Assets

23.0m15.3m12.5m8.3m11.7m28.7m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Cash

23.6m2.7m6.0m3.3m10.3m11.5m8.2m10.0m7.1m8.5m11.1m8.3m4.3m9.0m24.7m21.0m17.9m13.8m

Accounts Receivable

131.8k2.0k10.0k1.4k5.4k14.3k68.2k79.0k77.4k

Current Assets

24.4m20.3m17.6m16.1m22.2m20.2m15.9m12.5m7.6m9.1m11.4m8.6m6.2m10.6m28.7m23.5m24.4m20.2m

PP&E

13.1k56.7k480.9k464.3k428.2k495.0k468.0k444.4k423.7k392.9k332.0k308.2k320.0k662.0k645.7k663.1k621.4k566.6k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(6.6m)(12.2m)(21.1m)(13.0m)(12.4m)(16.6m)

Depreciation and Amortization

6.3k66.9k116.0k132.1k134.1k237.3k

Inventories

10.0k

Accounts Payable

146.4k642.0k(1.7m)(175.9k)(55.8k)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019

Net Income

(4.5m)(2.4m)(3.0m)(8.5m)(4.0m)(8.9m)(14.4m)(4.7m)(7.8m)(9.4m)(3.2m)(6.5m)(9.1m)(3.7m)(8.0m)(11.5m)(5.8m)(10.8m)

Depreciation and Amortization

2.9k2.2k41.9k25.6k53.9k84.4k32.4k65.6k98.8k33.1k66.7k101.0k44.1k108.4k171.2k67.2k122.0k

Accounts Payable

(112.9k)(273.5k)720.1k28.6k(555.6k)(570.0k)(385.2k)(494.3k)(1.5m)(1.5m)442.0k(202.2k)4.2k667.6k(211.9k)(55.4k)643.9k1.0m

Cash From Operating Activities

(4.8m)(2.4m)(7.3m)(4.5m)(8.2m)(12.4m)(4.9m)(8.9m)(10.8m)(3.0m)(5.4m)(9.4m)(3.8m)(11.8m)(15.7m)(4.2m)(8.2m)
USDY, 2019

Financial Leverage

1.4 x
Show all financial metrics

Heat Biologics Online and Social Media Presence

Embed Graph

Heat Biologics News and Updates

Heat Biologics CEO and Lead Director to Participate in German Investor Forums

John Prendergast, will host a series of investor forums and discussions across Germany on August 13-14, 2019. Heat management will meet with investors in Frankfurt, Dusseldorf, Stuttgart and Munich on the dates below.read more

Heat Biologics Completes Enrollment in Phase 2 Non-Small Cell Lung Cancer Trial

Lori McDermott, Heat’s VP of Clinical Development, said, “We are pleased to report that our Phase 2 enrollment targets were achieved on schedule. Last month, we reported promising interim results from the study showing that the addition of HS-110 to nivolumab may restore anti-tumor activity in patie…

Heat Biologics Blogs

Heat Biologics Reports Second Quarter 2019 Results and Provides Corporate Update

Completed enrollment of Phase 2 non-small cell lung cancer trial; on track to report top line data later this year Received FDA clearance of IND application for Phase 1 trial of HS-130 in combination with HS-110 for patients with advanced solid tumors refractory to standard of care DURHAM, NC / ACCE…

Heat Biologics Announces FDA Clearance of IND Application to Begin Phase 1 Trial of HS-130 in Combination with Heat’s HS-110

HS-130 is the first allogeneic, off-the-shelf, cell therapy approach utilizing OX40-mediated co-stimulation to enhance activation of dormant immune signalsClinical enrollment expected to commence in Q4 2019 DURHAM, NC / ACCESSWIRE / August 12, 2019 / Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-st…

Heat Biologics Announces Promising Interim Phase 2 Lung Cancer Data Suggesting that HS-110 Plus Nivolumab May Restore Clinical Benefit After Checkpoint Inhibitor Treatment Failure

Clinicalbenefit observed in 55% of patients receiving HS-110 plus nivolumab aftercheckpoint inhibitor treatment failure HS-110 incombination with nivolumab demonstrates clinical activity in low CD8+ TIL "coldtumor" patients and PD-L1 negative tumors Theoccurrence of dermal injection site reactions i…

Heat Biologics to Present at the 20th Annual B. Riley FBR Institutional Investor Conference

DURHAM, NC / ACCESSWIRE / May 20, 2019 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing therapies designed to activate a patient's immune system against cancer, today announced that it will be presenting at the 20th Annual B. Riley FBR Institutional Investor Conference o…

Heat Biologics Reports First Quarter 2019 Results and Provides Corporate Update

On track to complete enrollment of Phase 2 lung cancer trial in Q2 2019 and report additional interim data in Q4 2019 Anticipates receiving additional $6.9 million in grant funds after filing PTX-35 IND DURHAM, NC / ACCESSWIRE / May 15, 2019 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical…

Heat Biologics Lead Director to Present at the ChinaBio 2019 Conference in Shanghai

DURHAM, NC / ACCESSWIRE / May 6, 2019 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, today announced that John Prendergast, Heat Biologic's Lead Board member, is scheduled to present at the …
Show more

Heat Biologics Frequently Asked Questions

  • When was Heat Biologics founded?

    Heat Biologics was founded in 2008.

  • Who are Heat Biologics key executives?

    Heat Biologics's key executives are Jeffrey Wolf, Jeff Hutchins and George Peoples.

  • How many employees does Heat Biologics have?

    Heat Biologics has 30 employees.

  • Who are Heat Biologics competitors?

    Competitors of Heat Biologics include Cleveland BioLabs, Aptevo Therapeutics and XBiotech.

  • Where is Heat Biologics headquarters?

    Heat Biologics headquarters is located at 801 Capitola Dr #12, Durham.

  • Where are Heat Biologics offices?

    Heat Biologics has an office in Durham.

  • How many offices does Heat Biologics have?

    Heat Biologics has 1 office.